For example, to trap TGF-β molecules from binding to TGFBRs, 1D11 [81], and GC-1008 (Fresolimumab) [82] have been generated as TGF-β neutralization monoclonal antibodies and used in treatment of melanoma [83] and glioblastoma [84]. The gene discussed is TGFB1; the disease is melanoma.